Victrex declines after reporting divisional difficulties

Shares in FTSE 250 materials group Victrex moved lower on Tuesday after the group reported a decline in half year revenues in its Invibio Biomaterial Solutions business and warned of the ongoing challenges in some of its end markets.

Shares in FTSE 250 materials group Victrex moved lower on Tuesday after the group reported a decline in half year revenues in its Invibio Biomaterial Solutions business and warned of the ongoing challenges in some of its end markets.

The company blamed the revenue decline on the continued destocking at selected spine customers within the Invibio business, which was first reported in the second half of last year. Revenue for the division in the six months ended March 31st fell to £24.2m compared to £25.5m for the same period last year.

In a statement Victrex said: "We are pleased to report that, despite continued global economic challenges, group sales volume for the first half of 1,392 tonnes was ahead of the same period for last year (1,377 tonnes).

"As expected, this reflects a stronger performance from our Victrex Polymer Solutions business (VPS) in the second quarter with group sales volume of 752 tonnes compared to the first quarter of 640 tonnes. The first half has also seen continued progress from speciality products, predominantly driven by success in our Aptiv films business.

"We have made further progress with regulatory approvals in the spine market in Asia and the initial response to the launch of our dental product line, JUVORATM, has been positive."

Looking ahead, the initial order book for April was described as 'robust', the capital investment programme is on track, and there are strong opportunities to drive growth into new markets, applications and geographies.

The share price dropped 2.95% to 1,548p by 08:40.

NR

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Lab-grown meat: how “moo’s law” will drive innovation
Soft commodities

Lab-grown meat: how “moo’s law” will drive innovation

Jim Mellon and Anthony Chow, co-founders of Aim-listed Agronomics, explain why they believe that “cellular agriculture” will benefit from massive long…
16 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021